Head to Head Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus argenx (NASDAQ:ARGX)

argenx (NASDAQ:ARGX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares argenx and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Risk and Volatility

argenx has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for argenx and Acumen Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0	3	18	1	2.91
Acumen Pharmaceuticals	0	0	2	1	3.33

argenx currently has a consensus price target of $645.61, suggesting a potential downside of 0.46%. Acumen Pharmaceuticals has a consensus price target of $9.33, suggesting a potential upside of 410.02%. Given Acumen Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than argenx.

Insider & Institutional Ownership

60.3% of argenx shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 2.4% of argenx shares are owned by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares argenx and Acumen Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$1.86 billion	21.07	-$295.05 million	($0.88)	-737.07
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.38)	-1.33

Acumen Pharmaceuticals has lower revenue, but higher earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Acumen Pharmaceuticals beats argenx on 7 of the 13 factors compared between the two stocks.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.